The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biopharma Gains Another Shot on Goal With IND Approval

Research Report
  ()
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report
  ()
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report
  ()
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.

Target Price Boosted 400% on Biopharma Co.

Research Report
  ()
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Target Price Boosted on Canadian Pharma Co.

Research Report
  ()
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report
  ()
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report
  ()
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report
  ()
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report
  ()
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report
  ()
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Biopharma Co. Shows Large Potential Return

Research Report
  ()
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Biotech Co.'s Target Price Over Three Times Current

Research Report
  ()
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Biopharma Co. Partners With Merck for Combo Drug Trial

Research Report
  ()
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

Research Report
  ()
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Trial Results of New Drug for An Eye Disease 'Encouraging'

Research Report
  ()
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report.

Co. Uses RNA Editing as Treatment for Rare Disease

Research Report
  ()
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report
  ()
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report
  ()
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report
  ()
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report
  ()
Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report
  ()
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Higher Than Current

Research Report
  ()
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report
  ()
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Price Target on US Biopharma Co. Boosted by $15

Research Report
  ()
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

Showing Results: 1 to 25 of 46 Next